Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 99

1.

Update on extended release quetiapine fumarate in schizophrenia and bipolar disorders.

El-Khalili N.

Neuropsychiatr Dis Treat. 2012;8:523-36. doi: 10.2147/NDT.S14369. Epub 2012 Nov 8.

2.

Quetiapine: a review of its use in the management of bipolar depression.

Sanford M, Keating GM.

CNS Drugs. 2012 May 1;26(5):435-60. doi: 10.2165/11203840-000000000-00000. Review.

PMID:
22519923
3.

The management of schizophrenia: focus on extended-release quetiapine fumarate.

Peuskens J.

Neuropsychiatr Dis Treat. 2011;7:549-64. doi: 10.2147/NDT.S3380. Epub 2011 Sep 21.

4.

Summary of the comparative effectiveness review on off-label use of atypical antipsychotics.

Maher AR, Theodore G.

J Manag Care Pharm. 2012 Jun;18(5 Suppl B):S1-20. Review.

PMID:
22784311
5.

Quetiapine extended release: in schizophrenia.

Baldwin CM, Scott LJ.

CNS Drugs. 2009;23(3):261-9. doi: 10.2165/00023210-200923030-00007. Review.

PMID:
19320534
6.

Extended-release quetiapine as monotherapy for the treatment of adults with acute mania: a randomized, double-blind, 3-week trial.

Cutler AJ, Datto C, Nordenhem A, Minkwitz M, Acevedo L, Darko D.

Clin Ther. 2011 Nov;33(11):1643-58. doi: 10.1016/j.clinthera.2011.10.002. Epub 2011 Nov 4.

PMID:
22054797
7.

[Administration of once-daily extended release quetiapine in schizophrenic disorders].

Bartkó G.

Neuropsychopharmacol Hung. 2007 Dec;9(4):189-95. Hungarian.

8.
9.

Pharmacokinetic profile of the extended-release formulation of quetiapine fumarate (quetiapine XR): clinical implications.

Bui K, Earley W, Nyberg S.

Curr Med Res Opin. 2013 Jul;29(7):813-25. doi: 10.1185/03007995.2013.794774. Epub 2013 Apr 30. Review.

PMID:
23574265
10.

Comparison of D₂ dopamine receptor occupancy after oral administration of quetiapine fumarate immediate-release and extended-release formulations in healthy subjects.

Nord M, Nyberg S, Brogren J, Jucaite A, Halldin C, Farde L.

Int J Neuropsychopharmacol. 2011 Nov;14(10):1357-66. doi: 10.1017/S1461145711000514. Epub 2011 Apr 11.

11.

Pharmacokinetic profiles of extended release quetiapine fumarate compared with quetiapine immediate release.

Figueroa C, Brecher M, Hamer-Maansson JE, Winter H.

Prog Neuropsychopharmacol Biol Psychiatry. 2009 Mar 17;33(2):199-204. doi: 10.1016/j.pnpbp.2008.09.026. Epub 2008 Oct 9. Review.

PMID:
18948162
12.

Role of extended release quetiapine in the management of bipolar disorders.

Al Jurdi RK, Dixit LA, Sajatovic M.

Neuropsychiatr Dis Treat. 2010 Mar 24;6:29-35.

13.

Quetiapine extended release for the treatment of bipolar disorder.

Samalin L, Tremey A, Llorca PM.

Expert Rev Neurother. 2014 Sep;14(9):987-1005. doi: 10.1586/14737175.2014.946407. Epub 2014 Aug 6. Review.

PMID:
25096854
14.

Treatment patterns, healthcare resource utilization and costs in patients with bipolar disorder, newly treated with extended release or immediate release quetiapine fumarate using US healthcare administrative claims data.

Locklear JC, Alemayehu B, Brody RS, Chavoshi S, Tunceli O, Kern D, Earley WR.

Clin Ther. 2013 Dec;35(12):1923-32. doi: 10.1016/j.clinthera.2013.10.005. Epub 2013 Nov 22.

PMID:
24275622
15.
16.

Randomized, double-blind study of the efficacy and tolerability of extended release quetiapine fumarate (quetiapine XR) monotherapy in elderly patients with major depressive disorder.

Katila H, Mezhebovsky I, Mulroy A, Berggren L, Eriksson H, Earley W, Datto C.

Am J Geriatr Psychiatry. 2013 Aug;21(8):769-84. doi: 10.1016/j.jagp.2013.01.010. Epub 2013 Feb 6.

PMID:
23567397
17.

Efficacy and tolerability of once-daily extended release quetiapine fumarate in acute schizophrenia: a randomized, double-blind, placebo-controlled study.

Kahn RS, Schulz SC, Palazov VD, Reyes EB, Brecher M, Svensson O, Andersson HM, Meulien D; Study 132 Investigators.

J Clin Psychiatry. 2007 Jun;68(6):832-42.

PMID:
17592906
18.

Impact of extended-release quetiapine fumarate on hospitalization length and cost in schizophrenia and bipolar disorder patients: a retrospective, hospital-based, US-cohort analysis.

Locklear JC, Wahlqvist P, Gustafsson U, Udd M, Fajutrao L, Eriksson H.

J Comp Eff Res. 2014 Jul;3(4):335-44. doi: 10.2217/cer.14.27.

PMID:
25275231
19.

Effectiveness of the extended release formulation of quetiapine as monotherapy for the treatment of acute bipolar depression.

Suppes T, Datto C, Minkwitz M, Nordenhem A, Walker C, Darko D.

J Affect Disord. 2010 Feb;121(1-2):106-15. doi: 10.1016/j.jad.2009.10.007. Epub 2009 Nov 8. Erratum in: J Affect Disord. 2014 Oct 15;168:484. Corrected and republished in: J Affect Disord. 2014 Oct;168:485-93.

PMID:
19903574
20.

Comparison of the effects of quetiapine extended-release and quetiapine immediate-release on cognitive performance, sedation and patient satisfaction in patients with schizophrenia: a randomised, double-blind, crossover study (eXtRa).

Riedel M, Schmitz M, Østergaard PK, Ferrannini L, Franco MA, Alfano V, Vansvik ED.

Schizophr Res. 2015 Mar;162(1-3):162-8. doi: 10.1016/j.schres.2014.12.027. Epub 2015 Jan 12.

PMID:
25592805

Supplemental Content

Support Center